BioSpace News Archive

Umoja Biopharma, Inc., an immuno-oncology company pioneering off-the-shelf, integrated therapeutics that reprogram immune cells to treat patients with solid and hematologic malignancies, announced the appointment of Dieter Weinand to its Board of Directors where he will take on the role of Chair, effective November 17, 2022.

Nevro Corp. (NYSE: NVRO) today announced that two abstracts for Painful Diabetic Neuropathy (PDN) and Non-Surgical Back Pain (NSBP) were accepted for podium presentations at the 2023 North American Neuromodulation Society Annual Meeting (NANS 2023), and will be presented during the late-breaking plenary sessions on January 13-14, 2023 in Las Vegas, NV.

Third Pole Therapeutics, a privately held company developing critical life-sustaining cardio-pulmonary therapies, announced a $32M equity investment, from a large medical device innovator.

Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that the European Commission (EC) has designated upifitamab rilsodotin (UpRi) as an orphan medicinal product for the treatment of ovarian cancer.

Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of personalized therapeutic cancer vaccines (PTCV), today announced that a third patient has achieved a complete response (CR) among the first 24 patients (23 evaluable) enrolled in GT-30, an ongoing single-arm open-label multi-center Phase 1b/2a study.

Alto Neuroscience today announced top-line results from a Phase 1 human brain mechanism study of a series of novel combination drugs targeting the cyclic-AMP pathway, a key driver of cognition, memory, and mood in mental health conditions.

IMUNON, Inc. announced that the Compensation Committee of the Company’s Board of Directors approved the grant of inducement stock options to purchase a total of 19,000 shares of common stock and restricted stock grants totaling 4,000 shares of common stock as a material inducement to the employment to four individuals hired by IMUNON during the fourth quarter of 2022.

Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), announced today that its study titled “Thermophilic Filamentous Fungus C1-Cell-Cloned SARS-CoV-2-Spike-RBD-Subunit-Vaccine Adjuvanted with Aldydrogel®85 Protects K18-hACE2 Mice against Lethal Virus Challenge” has been published in VACCINES, a leading peer-reviewed scientific journal as part of the Special Issue “Vaccine Candidate against SARS-CoV-2”.

Oxford Biomedica Solutions LLC, an AAV manufacturing and innovation company, announced that it has signed agreements with three additional U.S. based, biotechnology companies.

Y-mAbs Therapeutics, Inc. announced that a clinical update for naxitamab and the Company’s SADA technology programs will be presented at the Company’s R&D event, which will take place Dec. 14, 2022 at 9 a.m. Eastern Time.